Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Medicine"
DOI: 10.2459/jcm.0000000000001346
Abstract: Letter to the Editor TheHeart Failure Association of the European Society of Cardiology (HFA) and the International Cardio-Oncology Society (ICOS) recently proposed the use of a chartbased tool for the baseline cardiovascular risk assessment of… read more here.
Keywords: patients scheduled; vegf agents; oncologic patients; anti vegf ... See more keywords